

EQA round: PAT1/22 - Direct Antiglobulin Test

Deadline: 03.06.2022

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
(1001) DAT (direct Coombs test)				
1	(14) Bio-Rad	>	3 Positive (1+)	3,5 %
		>	31 Positive (2+)	36 %
		>>>	11 Positive (3+)	13 %
	(17) Biogema	>	1 Positive (2+)	1,2 %
	(40) Ortho Clinical Diagnostics	>>>	3 Positive (3+)	3,5 %
	(80) DiaMed	>	7 Positive (2+)	8,2 %
		>>>	2 Positive (3+)	2,4 %
		>	1 Positive (4+)	1,2 %
	(159) Grifols	>	1 Positive (2+)	1,2 %
		>>>	17 Positive (3+)	20 %
		>	7 Positive (4+)	8,2 %
	(173) Sanguin	>	1 Positive (1+)	1,2 %
----- Total per sample: n = 85 -----		Success: 100 %	-----	
2	(14) Bio-Rad	>	8 Positive (1+)	9,4 %
		>>>	34 Positive (2+)	40 %
		>	3 Positive (3+)	3,5 %
	(17) Biogema	>	1 Positive (3+)	1,2 %
	(40) Ortho Clinical Diagnostics	>	3 Positive (3+)	3,5 %
	(80) DiaMed	>	3 Positive (1+)	3,5 %
		>>>	6 Positive (2+)	7,1 %
		>	1 Positive (4+)	1,2 %
	(159) Grifols	>>>	2 Positive (2+)	2,4 %
		>	17 Positive (3+)	20 %
		>	6 Positive (4+)	7,1 %
	(173) Sanguin	>>>	1 Positive (2+)	1,2 %
----- Total per sample: n = 85 -----		Success: 100 %	-----	
Total success: 100 %				

(1002) Sensitization specificity anti-IgG

1	(0) not specified	>	1 Positive (3+)	2,4 %
	(14) Bio-Rad	>>>	23 Positive (2+)	56 %
		>	1 Positive (3+)	2,4 %
	(80) DiaMed	>	4 Positive (1+)	9,8 %
		>>>	5 Positive (2+)	12 %
		>	1 Positive (4+)	2,4 %
	(159) Grifols	>>>	2 Positive (2+)	4,9 %
		>	4 Positive (3+)	9,8 %
----- Total per sample: n = 41 -----		Success: 100 %	-----	
2	(0) not specified	>	1 Positive (3+)	2,4 %
	(14) Bio-Rad	>	2 Positive (1+)	4,9 %
		>>>	19 Positive (2+)	46 %
		>	3 Positive (3+)	7,3 %
	(80) DiaMed		1 Negative	2,4 %
		>	1 Positive (1+)	2,4 %
		>>>	7 Positive (2+)	17 %
		>	1 Positive (4+)	2,4 %
	(159) Grifols	>	3 Positive (3+)	7,3 %
		>	3 Positive (4+)	7,3 %
----- Total per sample: n = 41 -----		Success: 98 %	-----	
Total success: 98 %				

(1003) Sensitization specificity anti-IgA

1	(14) Bio-Rad	>>>	23 Negative	72 %
	(80) DiaMed	>>>	9 Negative	28 %
----- Total per sample: n = 32 -----		Success: 100 %	-----	
2	(14) Bio-Rad	>>>	23 Negative	72 %
	(80) DiaMed	>>>	9 Negative	28 %
----- Total per sample: n = 32 -----		Success: 100 %	-----	
Total success: 100 %				

(1004) Sensitization specificity anti-IgM

1	(14) Bio-Rad	>>>	23 Negative	72 %
	(80) DiaMed	>>>	9 Negative	28 %
----- Total per sample: n = 32 -----		Success: 100 %	-----	
2	(14) Bio-Rad	>>>	23 Negative	72 %
	(80) DiaMed	>>>	9 Negative	28 %
----- Total per sample: n = 32 -----		Success: 100 %	-----	

Test		N	Result	N _{rel}
Sample	Group			
Total success: 100 %				
(1005) Sensitization specificity anti-C3c				
1	(14) Bio-Rad	>>>	21 Negative	66 %
		>	2 Positive (1+)	6,3 %
	(80) DiaMed	>>>	9 Negative	28 %
----- Total per sample: n = 32 -----		Success: 100 %		
2	(14) Bio-Rad	>>>	23 Negative	72 %
	(80) DiaMed	>>>	9 Negative	28 %
----- Total per sample: n = 32 -----		Success: 100 %		
Total success: 100 %				
(1006) Sensitization specificity anti-C3d				
1	(0) not specified	>	1 Positive (2+)	2,6 %
	(14) Bio-Rad		2 Negative	5,1 %
		>>>	22 Positive (1+)	56 %
	(80) DiaMed		2 Negative	5,1 %
		>>>	7 Positive (1+)	18 %
		>	1 Positive (2+)	2,6 %
	(159) Grifols	>>>	2 Positive (1+)	5,1 %
		>	2 Positive (2+)	5,1 %
----- Total per sample: n = 39 -----		Success: 90 %		
2	(0) not specified	>>>	1 Negative	2,6 %
	(14) Bio-Rad	>>>	24 Negative	62 %
	(80) DiaMed	>>>	10 Negative	26 %
	(159) Grifols	>>>	4 Negative	10 %
----- Total per sample: n = 39 -----		Success: 100 %		
Total success: 90 %				
(1008) Col. agglut: Quantif. IgG-DAT				
1	(14) Bio-Rad		2 Negative	8,7 %
		>>>	14 1:10	61 %
	(80) DiaMed		1 Negative	4,3 %
		>>>	6 1:10	26 %
----- Total per sample: n = 23 -----		Success: 87 %		
2	(14) Bio-Rad	>>>	12 Negative	52 %
			4 1:10	17 %
	(80) DiaMed	>>>	7 Negative	30 %
----- Total per sample: n = 23 -----		Success: 83 %		
Total success: 70 %				
(1009) Col. agglut: Subclass IgG1 1:1				
1	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	7 Negative	30 %
----- Total per sample: n = 23 -----		Success: 100 %		
2	(14) Bio-Rad	>>>	15 Negative	65 %
			1 Positive (1+)	4,3 %
	(80) DiaMed	>>>	6 Negative	26 %
			1 Positive (1+)	4,3 %
----- Total per sample: n = 23 -----		Success: 91 %		
Total success: 91 %				
(1010) Col. agglut: Subclass IgG1 1:100				
1	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	7 Negative	30 %
----- Total per sample: n = 23 -----		Success: 100 %		
2	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	7 Negative	30 %
----- Total per sample: n = 23 -----		Success: 100 %		
Total success: 100 %				
(1011) Col. agglut: Subclass IgG3 1:1				
1	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	7 Negative	30 %
----- Total per sample: n = 23 -----		Success: 100 %		
2	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	7 Negative	30 %
----- Total per sample: n = 23 -----		Success: 100 %		
Total success: 100 %				
(1012) Col. agglut: Subclass IgG3 1:100				
1	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	7 Negative	30 %
----- Total per sample: n = 23 -----		Success: 100 %		

EQA round: PAT1/22 - Direct Antiglobulin Test

Deadline: 03.06.2022

Test	Sample	Group	N	Result	N _{rel}
	2	(14) Bio-Rad	>>> 16	Negative	70 %
		(80) DiaMed	>>> 7	Negative	30 %
----- Total per sample: n = 23 ----- Success: 100 % -----					
Total success: 100 %					

(1019) AB0 blood group

1	(14) Bio-Rad	>>> 18	Blood group: 0	32 %	
	(40) Ortho Clinical Diagnostics	>>> 2	Blood group: 0	3,6 %	
	(64) Exbio Olomouc	>>> 1	Blood group: 0	1,8 %	
	(80) DiaMed	>>> 2	Blood group: 0	3,6 %	
	(159) Grifols	>>> 17	Blood group: 0	30 %	
	(172) Immucor	>>> 5	Blood group: 0	8,9 %	
	(173) Sanguin	>>> 7	Blood group: 0	13 %	
	(174) IVT Imuno	>>> 3	Blood group: 0	5,4 %	
	(183) Immunodiagnostic Systems	>>> 1	Blood group: 0	1,8 %	
----- Total per sample: n = 56 ----- Success: 100 % -----					
2	(14) Bio-Rad	>>> 18	Blood group: A	32 %	
	(40) Ortho Clinical Diagnostics	>>> 2	Blood group: A	3,6 %	
	(64) Exbio Olomouc	>>> 1	Blood group: A	1,8 %	
	(80) DiaMed	>>> 2	Blood group: A	3,6 %	
	(159) Grifols	>>> 17	Blood group: A	30 %	
	(172) Immucor	>>> 5	Blood group: A	8,9 %	
	(173) Sanguin	>>> 7	Blood group: A	13 %	
	(174) IVT Imuno	>>> 3	Blood group: A	5,4 %	
	(183) Immunodiagnostic Systems	>>> 1	Blood group: A	1,8 %	
----- Total per sample: n = 56 ----- Success: 100 % -----					
Total success: 100 %					

(1020) Rh D antigen

1	(14) Bio-Rad	>>> 23	Positive (RhD+)	41 %	
	(40) Ortho Clinical Diagnostics	>>> 2	Positive (RhD+)	3,6 %	
	(52) Dynex	>>> 1	Positive (RhD+)	1,8 %	
	(64) Exbio Olomouc	>>> 1	Positive (RhD+)	1,8 %	
	(80) DiaMed	>>> 2	Positive (RhD+)	3,6 %	
	(159) Grifols	>>> 17	Positive (RhD+)	30 %	
	(170) Biotest	>>> 1	Positive (RhD+)	1,8 %	
	(172) Immucor	>>> 4	Positive (RhD+)	7,1 %	
	(173) Sanguin	>>> 4	Positive (RhD+)	7,1 %	
	(183) Immunodiagnostic Systems	>>> 1	Positive (RhD+)	1,8 %	
----- Total per sample: n = 56 ----- Success: 100 % -----					
2	(14) Bio-Rad	>>> 23	Positive (RhD+)	41 %	
	(40) Ortho Clinical Diagnostics	>>> 2	Positive (RhD+)	3,6 %	
	(52) Dynex	>>> 1	Positive (RhD+)	1,8 %	
	(64) Exbio Olomouc	>>> 1	Positive (RhD+)	1,8 %	
	(80) DiaMed	>>> 2	Positive (RhD+)	3,6 %	
	(159) Grifols	>>> 17	Positive (RhD+)	30 %	
	(170) Biotest	>>> 1	Positive (RhD+)	1,8 %	
	(172) Immucor	>>> 4	Positive (RhD+)	7,1 %	
	(173) Sanguin	>>> 4	Positive (RhD+)	7,1 %	
	(183) Immunodiagnostic Systems	>>> 1	Positive (RhD+)	1,8 %	
----- Total per sample: n = 56 ----- Success: 100 % -----					
Total success: 100 %					

(1021) Antigen C

1	(14) Bio-Rad	>>> 16	Positive	35 %	
	(50) Merck	>>> 1	Positive	2,2 %	
	(80) DiaMed	>>> 2	Positive	4,3 %	
	(159) Grifols	>>> 20	Positive	43 %	
	(172) Immucor	>>> 3	Positive	6,5 %	
	(173) Sanguin	>>> 2	Positive	4,3 %	
	(183) Immunodiagnostic Systems	>>> 1	Positive	2,2 %	
	(999) another manufacturer	>>> 1	Positive	2,2 %	
----- Total per sample: n = 46 ----- Success: 100 % -----					
2	(14) Bio-Rad	>>> 16	Positive	35 %	
	(50) Merck	>>> 1	Positive	2,2 %	
	(80) DiaMed	>>> 2	Positive	4,3 %	
	(159) Grifols	>>> 20	Positive	43 %	
	(172) Immucor	>>> 3	Positive	6,5 %	
	(173) Sanguin	>>> 2	Positive	4,3 %	
	(183) Immunodiagnostic Systems	>>> 1	Positive	2,2 %	

EQA round: PAT1/22 - Direct Antiglobulin Test

Deadline: 03.06.2022

Test	Sample	Group	N	Result	N _{rel}
	2	(999) another manufacturer	>>>	1 Positive	2,2 %
	Total per sample: n = 46		Success: 100 %		
	Total success: 100 %				
(1022) Antigen c					
	1	(14) Bio-Rad	>>>	16 Positive	35 %
		(50) Merck	>>>	1 Positive	2,2 %
		(80) DiaMed	>>>	2 Positive	4,3 %
		(159) Grifols	>>>	20 Positive	43 %
		(172) Immucor	>>>	3 Positive	6,5 %
		(173) Sanguin	>>>	2 Positive	4,3 %
		(183) Immunodiagnostic Systems	>>>	1 Positive	2,2 %
		(999) another manufacturer	>>>	1 Positive	2,2 %
	Total per sample: n = 46		Success: 100 %		
	2	(14) Bio-Rad	>>>	16 Positive	35 %
		(50) Merck	>>>	1 Positive	2,2 %
		(80) DiaMed	>>>	2 Positive	4,3 %
		(159) Grifols	>>>	20 Positive	43 %
		(172) Immucor	>>>	3 Positive	6,5 %
		(173) Sanguin	>>>	2 Positive	4,3 %
		(183) Immunodiagnostic Systems	>>>	1 Positive	2,2 %
		(999) another manufacturer	>>>	1 Positive	2,2 %
	Total per sample: n = 46		Success: 100 %		
	Total success: 100 %				
(1023) Antigen Cw					
	1	(14) Bio-Rad	>>>	6 Negative	15 %
		(50) Merck	>>>	1 Negative	2,6 %
		(159) Grifols	>>>	20 Negative	51 %
		(170) Biotest	>>>	1 Negative	2,6 %
		(172) Immucor	>>>	3 Negative	7,7 %
		(173) Sanguin	>>>	6 Negative	15 %
		(174) IVT Imuno	>>>	1 Negative	2,6 %
		(999) another manufacturer	>>>	1 Negative	2,6 %
	Total per sample: n = 39		Success: 100 %		
	2	(14) Bio-Rad	>>>	6 Negative	15 %
		(50) Merck	>>>	1 Negative	2,6 %
		(159) Grifols	>>>	20 Negative	51 %
		(170) Biotest	>>>	1 Negative	2,6 %
		(172) Immucor	>>>	3 Negative	7,7 %
		(173) Sanguin	>>>	6 Negative	15 %
		(174) IVT Imuno	>>>	1 Negative	2,6 %
		(999) another manufacturer	>>>	1 Negative	2,6 %
	Total per sample: n = 39		Success: 100 %		
	Total success: 100 %				
(1024) Antigen E					
	1	(14) Bio-Rad	>>>	17 Negative	36 %
		(50) Merck	>>>	1 Negative	2,1 %
		(80) DiaMed	>>>	2 Negative	4,3 %
		(159) Grifols	>>>	20 Negative	43 %
		(172) Immucor	>>>	3 Negative	6,4 %
		(173) Sanguin	>>>	2 Negative	4,3 %
		(183) Immunodiagnostic Systems	>>>	1 Negative	2,1 %
		(999) another manufacturer	>>>	1 Negative	2,1 %
	Total per sample: n = 47		Success: 100 %		
	2	(14) Bio-Rad	>>>	17 Negative	36 %
		(50) Merck	>>>	1 Negative	2,1 %
		(80) DiaMed	>>>	2 Negative	4,3 %
		(159) Grifols	>>>	20 Negative	43 %
		(172) Immucor	>>>	3 Negative	6,4 %
		(173) Sanguin	>>>	2 Negative	4,3 %
		(183) Immunodiagnostic Systems	>>>	1 Negative	2,1 %
		(999) another manufacturer	>>>	1 Negative	2,1 %
	Total per sample: n = 47		Success: 100 %		
	Total success: 100 %				
(1025) Antigen e					
	1	(14) Bio-Rad	>>>	16 Positive	35 %
		(50) Merck	>>>	1 Positive	2,2 %
		(80) DiaMed	>>>	2 Positive	4,3 %

EQA round: PAT1/22 - Direct Antiglobulin Test

Deadline: 03.06.2022

Test	Sample	Group	N	Result	N _{rel}
1	(159)	Grifols	>>> 20	Positive	43 %
	(172)	Immucor	>>> 3	Positive	6,5 %
	(173)	Sanguin	>>> 2	Positive	4,3 %
	(183)	Immunodiagnostic Systems	>>> 1	Positive	2,2 %
	(999)	another manufacturer	>>> 1	Positive	2,2 %
	Total per sample: n = 46			Success: 100 %	
2	(14)	Bio-Rad	>>> 16	Positive	35 %
	(50)	Merck	>>> 1	Positive	2,2 %
	(80)	DiaMed	>>> 2	Positive	4,3 %
	(159)	Grifols	>>> 20	Positive	43 %
	(172)	Immucor	>>> 3	Positive	6,5 %
	(173)	Sanguin	>>> 2	Positive	4,3 %
	(183)	Immunodiagnostic Systems	>>> 1	Positive	2,2 %
	(999)	another manufacturer	>>> 1	Positive	2,2 %
Total per sample: n = 46			Success: 100 %		
Total success: 100 %					

(1026) Antigen K

1	(14)	Bio-Rad	>>> 16	Negative	33 %
	(50)	Merck	>>> 1	Negative	2,1 %
	(80)	DiaMed	>>> 2	Negative	4,2 %
	(159)	Grifols	>>> 21	Negative	44 %
	(172)	Immucor	>>> 3	Negative	6,3 %
	(173)	Sanguin	>>> 2	Negative	4,2 %
	(174)	IVT Imuno	>>> 1	Negative	2,1 %
	(183)	Immunodiagnostic Systems	>>> 1	Negative	2,1 %
	(999)	another manufacturer	>>> 1	Negative	2,1 %
Total per sample: n = 48			Success: 100 %		
2	(14)	Bio-Rad	>>> 16	Negative	33 %
	(50)	Merck	>>> 1	Negative	2,1 %
	(80)	DiaMed	>>> 2	Negative	4,2 %
	(159)	Grifols	>>> 21	Negative	44 %
	(172)	Immucor	>>> 3	Negative	6,3 %
	(173)	Sanguin	>>> 2	Negative	4,2 %
	(174)	IVT Imuno	>>> 1	Negative	2,1 %
	(183)	Immunodiagnostic Systems	>>> 1	Negative	2,1 %
	(999)	another manufacturer	>>> 1	Negative	2,1 %
Total per sample: n = 48			Success: 100 %		
Total success: 100 %					

(1027) Antigen k

1	(14)	Bio-Rad	>>> 5	Positive	19 %
	(64)	Exbio Olomouc	>>> 3	Positive	11 %
	(80)	DiaMed	>>> 3	Positive	11 %
	(159)	Grifols	>>> 1	Positive	3,7 %
	(172)	Immucor	>>> 2	Positive	7,4 %
	(173)	Sanguin	>>> 13	Positive	48 %
Total per sample: n = 27			Success: 100 %		
2	(14)	Bio-Rad	>>> 5	Positive	19 %
	(64)	Exbio Olomouc	>>> 3	Positive	11 %
	(80)	DiaMed	>>> 3	Positive	11 %
	(159)	Grifols	>>> 1	Positive	3,7 %
	(172)	Immucor	>>> 2	Positive	7,4 %
	(173)	Sanguin	>>> 13	Positive	48 %
Total per sample: n = 27			Success: 100 %		
Total success: 100 %					

(1028) Antigen M

1	(6)	APR	>>> 1	Positive	4,0 %
	(14)	Bio-Rad	>>> 3	Positive	12 %
	(64)	Exbio Olomouc	>>> 1	Positive	4,0 %
	(80)	DiaMed	>>> 2	Positive	8,0 %
	(159)	Grifols	>>> 5	Positive	20 %
	(172)	Immucor	>>> 6	Positive	24 %
	(173)	Sanguin	>>> 3	Positive	12 %
	(174)	IVT Imuno	>>> 1	Positive	4,0 %
	(183)	Immunodiagnostic Systems	>>> 1	Positive	4,0 %
	(203)	ANTITOXIN	>>> 2	Positive	8,0 %
Total per sample: n = 25			Success: 100 %		
2	(6)	APR	>>> 1	Positive	4,0 %

EQA round: PAT1/22 - Direct Antiglobulin Test

Deadline: 03.06.2022

Test	Sample	Group	N	Result	N _{rel}	
	2	(14) Bio-Rad	>>>	3	Positive	12 %
		(64) Exbio Olomouc	>>>	1	Positive	4,0 %
		(80) DiaMed	>>>	2	Positive	8,0 %
		(159) Grifols	>>>	5	Positive	20 %
		(172) Immucor	>>>	6	Positive	24 %
		(173) Sanguin	>>>	3	Positive	12 %
		(174) IVT Imuno	>>>	1	Positive	4,0 %
		(183) Immunodiagnostic Systems	>>>	1	Positive	4,0 %
		(203) ANTITOXIN	>>>	2	Positive	8,0 %
Total per sample: n = 25			Success: 100 %			
Total success: 100 %						

(1029) Antigen N

1	(6) APR	>>>	1	Positive	4,3 %
	(14) Bio-Rad	>>>	3	Positive	13 %
	(64) Exbio Olomouc	>>>	1	Positive	4,3 %
	(80) DiaMed	>>>	2	Positive	8,7 %
	(159) Grifols	>>>	5	Positive	22 %
	(172) Immucor	>>>	4	Positive	17 %
	(173) Sanguin	>>>	3	Positive	13 %
	(174) IVT Imuno	>>>	1	Positive	4,3 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	4,3 %
(203) ANTITOXIN	>>>	2	Positive	8,7 %	
Total per sample: n = 23			Success: 100 %		
2	(6) APR	>>>	1	Negative	4,3 %
	(14) Bio-Rad	>>>	3	Negative	13 %
	(64) Exbio Olomouc	>>>	1	Negative	4,3 %
	(80) DiaMed	>>>	2	Negative	8,7 %
	(159) Grifols	>>>	5	Negative	22 %
	(172) Immucor	>>>	4	Negative	17 %
	(173) Sanguin	>>>	3	Negative	13 %
	(174) IVT Imuno	>>>	1	Negative	4,3 %
	(183) Immunodiagnostic Systems	>>>	1	Negative	4,3 %
(203) ANTITOXIN	>>>	2	Negative	8,7 %	
Total per sample: n = 23			Success: 100 %		
Total success: 100 %					

(1030) Antigen S

1	(6) APR	>>>	1	Positive	3,8 %	
	(14) Bio-Rad	>>>	2	Positive	7,7 %	
	(64) Exbio Olomouc	>>>	1	Positive	3,8 %	
	(80) DiaMed	>>>	1	Positive	3,8 %	
	(159) Grifols	>>>	5	Positive	19 %	
	(172) Immucor	>>>	8	Positive	31 %	
	(173) Sanguin	>>>	7	Positive	27 %	
	(183) Immunodiagnostic Systems	>>>	1	Positive	3,8 %	
Total per sample: n = 26			Success: 100 %			
2	(6) APR	>>>	1	Negative	3,8 %	
	(14) Bio-Rad	>>>	2	Negative	7,7 %	
	(64) Exbio Olomouc	>>>	1	Negative	3,8 %	
	(80) DiaMed	>>>	1	Negative	3,8 %	
	(159) Grifols	>>>	2	Negative	7,7 %	
				3	Positive	12 %
	(172) Immucor	>>>	8	Negative	31 %	
	(173) Sanguin	>>>	7	Negative	27 %	
(183) Immunodiagnostic Systems	>>>	1	Negative	3,8 %		
Total per sample: n = 26			Success: 88 %			
Total success: 88 %						

(1031) Antigen s

1	(6) APR	>>>	1	Negative	5,0 %	
	(14) Bio-Rad	>>>	1	Negative	5,0 %	
	(64) Exbio Olomouc	>>>	1	Negative	5,0 %	
	(80) DiaMed	>>>	1	Negative	5,0 %	
	(159) Grifols	>>>	2	Negative	10 %	
				3	Positive	15 %
	(172) Immucor	>>>	9	Negative	45 %	
			1	Positive	5,0 %	
(173) Sanguin	>>>	1	Negative	5,0 %		
Total per sample: n = 20			Success: 80 %			

Test	Sample	Group	N	Result	N _{rel}
	2	(6) APR	>>>	1 Positive	5,0 %
		(14) Bio-Rad	>>>	1 Positive	5,0 %
		(64) Exbio Olomouc	>>>	1 Positive	5,0 %
		(80) DiaMed	>>>	1 Positive	5,0 %
		(159) Grifols	>>>	5 Positive	25 %
		(172) Immucor	>>>	10 Positive	50 %
		(173) Sanguin	>>>	1 Positive	5,0 %
	Total per sample: n = 20		Success: 100 %		
Total success: 80 %					

(1032) Antigen P1

1	(14) Bio-Rad	>>>	3 Positive	14 %	
	(64) Exbio Olomouc	>>>	3 Positive	14 %	
	(80) DiaMed	>>>	2 Positive	9,1 %	
	(159) Grifols	>>>	3 Positive	14 %	
	(172) Immucor	>>>	5 Positive	23 %	
	(173) Sanguin	>>>	6 Positive	27 %	
	Total per sample: n = 22		Success: 100 %		
2	(14) Bio-Rad	>>>	3 Positive	14 %	
	(64) Exbio Olomouc	>>>	3 Positive	14 %	
	(80) DiaMed	>>>	2 Positive	9,1 %	
	(159) Grifols	>>>	3 Positive	14 %	
	(172) Immucor	>>>	5 Positive	23 %	
	(173) Sanguin	>>>	6 Positive	27 %	
Total per sample: n = 22		Success: 100 %			
Total success: 100 %					

(1033) Antigen Jka

1	(14) Bio-Rad	>>>	3 Negative	10 %	
	(52) Dynex	>>>	2 Negative	6,9 %	
	(64) Exbio Olomouc	>>>	2 Negative	6,9 %	
	(80) DiaMed	>>>	1 Negative	3,4 %	
	(159) Grifols	>>>	8 Negative	28 %	
	(172) Immucor	>>>	6 Negative	21 %	
	(173) Sanguin	>>>	7 Negative	24 %	
Total per sample: n = 29		Success: 100 %			
2	(14) Bio-Rad	>>>	3 Positive	10 %	
	(52) Dynex	>>>	2 Positive	6,9 %	
	(64) Exbio Olomouc	>>>	2 Positive	6,9 %	
	(80) DiaMed	>>>	1 Positive	3,4 %	
	(159) Grifols	>>>	8 Positive	28 %	
	(172) Immucor	>>>	6 Positive	21 %	
	(173) Sanguin	>>>	7 Positive	24 %	
Total per sample: n = 29		Success: 100 %			
Total success: 100 %					

(1034) Antigen Jkb

1	(14) Bio-Rad	>>>	2 Positive	7,1 %	
	(52) Dynex	>>>	1 Positive	3,6 %	
	(64) Exbio Olomouc	>>>	2 Positive	7,1 %	
	(80) DiaMed	>>>	1 Positive	3,6 %	
	(159) Grifols	>>>	8 Positive	29 %	
	(172) Immucor	>>>	6 Positive	21 %	
	(173) Sanguin	>>>	8 Positive	29 %	
Total per sample: n = 28		Success: 100 %			
2	(14) Bio-Rad	>>>	2 Positive	7,1 %	
	(52) Dynex	>>>	1 Positive	3,6 %	
	(64) Exbio Olomouc	>>>	2 Positive	7,1 %	
	(80) DiaMed	>>>	1 Positive	3,6 %	
	(159) Grifols	>>>	8 Positive	29 %	
	(172) Immucor	>>>	6 Positive	21 %	
	(173) Sanguin	>>>	8 Positive	29 %	
Total per sample: n = 28		Success: 100 %			
Total success: 100 %					

(1035) Antigen Lea

1	(14) Bio-Rad	>>>	3 Negative	15 %
	(64) Exbio Olomouc	>>>	2 Negative	10 %
	(80) DiaMed	>>>	1 Negative	5,0 %
	(159) Grifols	>>>	4 Negative	20 %
	(172) Immucor	>>>	7 Negative	35 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT1/22 - Direct Antiglobulin Test

Deadline: 03.06.2022

Test

Sample	Group	N	Result	N _{rel}
1	(173) Sanguin	>>>	3 Negative	15 %
----- Total per sample: n = 20 -----		Success: 100 %	-----	
2	(14) Bio-Rad	>>>	3 Negative	15 %
	(64) Exbio Olomouc	>>>	2 Negative	10 %
	(80) DiaMed	>>>	1 Negative	5,0 %
	(159) Grifols	>>>	4 Negative	20 %
	(172) Immucor	>>>	7 Negative	35 %
	(173) Sanguin	>>>	3 Negative	15 %
----- Total per sample: n = 20 -----		Success: 100 %	-----	
Total success: 100 %				

(1036) Antigen Leb

1	(14) Bio-Rad	>>>	3 Positive	15 %
	(64) Exbio Olomouc	>>>	2 Positive	10 %
	(80) DiaMed	>>>	1 Positive	5,0 %
	(159) Grifols	>>>	4 Positive	20 %
	(172) Immucor	>>>	7 Positive	35 %
	(173) Sanguin	>>>	3 Positive	15 %
----- Total per sample: n = 20 -----		Success: 100 %	-----	
2	(14) Bio-Rad	>>>	3 Positive	15 %
	(64) Exbio Olomouc	>>>	2 Positive	10 %
	(80) DiaMed	>>>	1 Positive	5,0 %
	(159) Grifols	>>>	4 Positive	20 %
	(172) Immucor	>>>	7 Positive	35 %
	(173) Sanguin	>>>	3 Positive	15 %
----- Total per sample: n = 20 -----		Success: 100 %	-----	
Total success: 100 %				

st_kl

End of report

Printed: 09.06.2022